Treatment of advanced Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) after failure of MOPP therapy
- PMID: 77716
- DOI: 10.1002/1097-0142(197806)41:6<2107::aid-cncr2820410606>3.0.co;2-l
Treatment of advanced Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) after failure of MOPP therapy
Abstract
From June 19, 1975 to December 22, 1976, twenty-seven patients with advanced Hodgkin's disease who failed MOPP (nitrogen mustard, vincristine, procarbazine and prednisone) were treated with adriamycin, bleomycin, vinblastine, and imidazole carboxamide, (ABVD). Complete response (CR) was achieved in 22% of patients and partial response was achieved in 15%. No response was observed in 63% of patients. With a median duration of follow-up for CR patients of only 10.5 months, two of the six CR patients have already relapsed. In this series of patients ABVD was not an effective curative regimen for patients with Hodgkin's disease who have failed MOPP.
Similar articles
-
Combination chemotherapy of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, dacarbazine and vinblastine (ABDV).Cancer. 1977 Apr;39(4):1382-6. doi: 10.1002/1097-0142(197704)39:4<1382::aid-cncr2820390405>3.0.co;2-f. Cancer. 1977. PMID: 66972
-
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.J Clin Oncol. 2003 Feb 15;21(4):607-14. doi: 10.1200/JCO.2003.12.086. J Clin Oncol. 2003. PMID: 12586796 Clinical Trial.
-
Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.Cancer Treat Rep. 1984 Jul-Aug;68(7-8):947-51. Cancer Treat Rep. 1984. PMID: 6204754
-
Can MOPP be replaced in the treatment of advanced Hodgkin's disease?Semin Oncol. 1990 Feb;17(1 Suppl 2):2-6. Semin Oncol. 1990. PMID: 1689509 Review.
-
Advanced Hodgkin's disease: ABVD is better, yet is not good enough!J Clin Oncol. 2003 Feb 15;21(4):583-5. doi: 10.1200/JCO.2003.11.072. J Clin Oncol. 2003. PMID: 12586791 Review. No abstract available.
Cited by
-
Hodgkin's disease in adults: the challenge.Postgrad Med J. 1985 Feb;61(712):103-7. doi: 10.1136/pgmj.61.712.103. Postgrad Med J. 1985. PMID: 3838586 Free PMC article. No abstract available.
-
[Hodgkin's disease. Results in diagnosis and treatment (author's transl)].Klin Wochenschr. 1979 Apr 17;57(8):371-81. doi: 10.1007/BF01480475. Klin Wochenschr. 1979. PMID: 156814 Review. German.
-
Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD).Cancer Chemother Pharmacol. 1979;2(2):101-5. doi: 10.1007/BF00254081. Cancer Chemother Pharmacol. 1979. PMID: 93984 Clinical Trial.
-
Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV).Cancer Chemother Pharmacol. 1983;11(2):80-5. doi: 10.1007/BF00254250. Cancer Chemother Pharmacol. 1983. PMID: 6194913
-
Phase I trial of tallysomycin S10b, a bleomycin analogue.Invest New Drugs. 1990 May;8(2):171-80. doi: 10.1007/BF00177253. Invest New Drugs. 1990. PMID: 1696567